Get the Stockscreener App
78.26
10.94%
7.72
Pre-market:
80.50
2.24
+2.86%
Praxis Precision Medicines Inc stock is traded at $78.26, with a volume of 505.28K.
It is up +10.94% in the last 24 hours and up +2.27% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
See More
Previous Close:
$70.54
Open:
$72.28
24h Volume:
505.28K
Relative Volume:
1.57
Market Cap:
$1.46B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-8.5344
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
+18.86%
1M Performance:
+2.27%
6M Performance:
+42.39%
1Y Performance:
+109.14%
1-Day Range:
$70.00
$78.80
1-Week Range:
$66.00
$78.80
52-Week Range:
$33.01
$86.93
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
78.26 | 1.46B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Truist Financial Issues Positive Forecast for Praxis Precision Medicines (NASDAQ:PRAX) Stock Price - Defense World
Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts - Benzinga
Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 8.5% Following Analyst Upgrade - MarketBeat
Truist raises Praxis stock target to $175 on study optimism - MSN
Truist raises Praxis stock target to $175 on study optimism By Investing.com - Investing.com UK
Ellsworth Advisors LLC Invests $627,000 in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Short Interest Update - MarketBeat
Trend Tracker for (PRAX) - Stock Traders Daily
Assenagon Asset Management S.A. Has $43.03 Million Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines Unveils Ambitious 2025 Strategy: 4 Pivotal Trial Readouts, $470M Cash Runway - StockTitan
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities - The Bakersfield Californian
Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 8.9%Here's Why - MarketBeat
(PRAX) Trading Report - Stock Traders Daily
Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference - The Manila Times
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Long Term Trading Analysis for (PRAX) - Stock Traders Daily
Geode Capital Management LLC Has $22.95 Million Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Bought by Barclays PLC - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Acquired by Barclays PLC - MarketBeat
Praxis Precision Medicines: Multiple Potential Drivers (NASDAQ:PRAX) - Seeking Alpha
Praxis Precision Medicines Inc (NASDAQ: PRAX) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Franklin Resources Inc. Grows Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
State Street Corp Has $45.44 Million Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $913,000 Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
(PRAX) Technical Data - Stock Traders Daily
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine - The Bakersfield Californian
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome - GlobeNewswire
Praxis Precision Medicines Secures Key FDA Designation for Promising Epilepsy Drug Relutrigine - StockTitan
Praxis Precision Medicines (NASDAQ:PRAX) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Wellington Management Group LLP Buys 168,394 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright - Defense World
BNP Paribas Financial Markets Has $548,000 Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
BNP Paribas Financial Markets Purchases 7,496 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation - Simply Wall St
HC Wainwright Reaffirms "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX) - MarketBeat
Expert Ratings For Praxis Precision Medicine - Benzinga
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat
Fmr LLC Trims Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Jefferies highlights Praxis Medicines as a 'top idea' for 2025, raises price target - Investing.com
The Manufacturers Life Insurance Company Reduces Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Where are the Opportunities in (PRAX) - Stock Traders Daily
Jacobs Levy Equity Management Inc. Cuts Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Janus Henderson Group PLC Purchases 141,881 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision management to meet with Oppenheimer - Nasdaq
RA Capital Management L.P. Has $43.84 Million Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
HighVista Strategies LLC Makes New $630,000 Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines to Present at Upcoming December Investor Conferences - The Manila Times
Praxis Precision Medicines to Present at Major Healthcare Investor Conferences in December - StockTitan
Walleye Capital LLC Buys New Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Baker BROS. Advisors LP Has $18.59 Million Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):